Haematology

News

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.

News

Lilly trumpets strong result for Jaypirca in CLL at EHA

New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.

News

Two boxes and vials of Talvey, different doses

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

News

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Incyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.

News

Roche doubles down on BTK with $2.3bn Nurix deal

Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.

News

AbbVie's Immunogen buy delivers rare cancer drug approval

AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Lilly trumpets strong result for Jaypirca in CLL at EHA

Data could move J&J's Talvey earlier in myeloma therapy

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Roche doubles down on BTK with $2.3bn Nurix deal

AbbVie's Immunogen buy delivers rare cancer drug approval

UK's Mission divests kidney drug to Dimerix for $292m

Discover a new era of healthcare panel engagement: Grounded ...

Haematology

Editor's Picks